UNLABELLED: An updated Council of the EU recommendation on cancer screening was adopted in December 2022 during the Czech EU presidency. The recommendation included prostate cancer as a suitable target disease for organised screening, and invited countries to proceed with piloting and further research. To support further discussions and actions to promote early detection of prostate cancer, an international conference in November 2022 (Prostaforum 2022) resulted in a joint declaration. Here we describe the EU policy background, summarise the preparation of the declaration and the key underlying evidence and expert recommendations, and report the text of the declaration. The declaration summarises the striking inequalities in prostate cancer burden in Europe and calls on all stakeholders to consider and support concrete steps for advancement of organised early detection of prostate cancer. Our aim is to request endorsement of the text and potential initiation of practical actions by all stakeholders to support the aims of the declaration. PATIENT SUMMARY: Prostate cancer is among the most frequent cancers and is one of the most common causes of cancer death among men. The European Union has recommended new pilot programmes for prostate cancer screening. The Prostaforum 2022 declaration invites all stakeholders to support this new recommendation with specific steps.

Department of Imaging Methods Medical Faculty Pilsen Charles University University Hospital Pilsen Pilsen Czechia

Department of Urology 2nd Faculty of Medicine Charles University Motol University Hospital Prague Czechia

Department of Urology 3rd Faculty of Medicine of Charles University and Faculty Thomayer Hospital Prague Czechia

Department of Urology Erasmus University Medical Centre Cancer Institute Rotterdam The Netherlands

Department of Urology Institute of Clinical Sciences Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

Department of Urology KU Leuven Leuven Belgium

Department of Urology Sahlgrenska University Hospital Gothenburg Sweden

European Association of Urology Policy Office Arnhem The Netherlands

Faculty of Medicine Masaryk University Brno Czechia

Ministry of Health of the Czech Republic Prague Czechia

National Screening Centre Institute of Health Information and Statistics of the Czech Republic Prague Czechia

See more in PubMed

European Council. Council updates its recommendation to screen for cancer. Brussels, Belgium: European Council; 2022. https://www.consilium.europa.eu/en/press/press-releases/2022/12/09/council-updates-its-recommendation-to-screen-for-cancer/.

Science Advice for Policy by European Academies . SAPEA; Berlin: 2022. Improving cancer screening in the European Union.

Institute of Health Information and Statistics of the Czech Republic. Prostaforum 2022. https://prostaforum.uzis.cz/en/.

Bokhorst L.P., Bangma C.H., van Leenders G.J., et al. Prostate-specific antigen–based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2014;65:329–336. PubMed

Eklund M., Jäderling F., Discacciati A., et al. MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med. 2021;385:908–920. PubMed

Van Poppel H., Roobol M.J., Chapple C.R., et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021. Eur Urol. 2021;80:703–711. PubMed

Van Poppel H., Hogenhout R., Albers P., van den Bergh R.C.N., Barentsz J.O., Roobol M.J. Early detection of prostate cancer in 2020 and beyond: facts and recommendations for the European Union and the European Commission. Eur Urol. 2021;79:327–329. PubMed

Van Poppel H., Albreht T., Basu P., Hogenhout R., Collen S., Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19:562–572. PubMed

Alterbeck M., Järbur E., Thimansson E., et al. Designing and implementing a population-based organised prostate cancer testing programme. Eur Urol Focus. 2022;8:1568–1574. PubMed

Hamdy F.C., Donovan J.L., Lane J.A., et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547–1558. PubMed

Ministry of Health of the Czech Republic. Modern cancer control: saving lives through smart solutions, output document. Prague, Czechia: Ministry of Health; 2022. https://www.mzcr.cz/modern-cancer-control-saving-lives-through-smart-solutions-output-document/.

European Cancer Information System. Prostate cancer factsheet in 2020 for EU-27 countries. Brussels, Belgium: European Commission; 2021. https://ecis.jrc.ec.europa.eu/factsheets.php.

Espina C., Soerjomataram I., Forman D., Martín-Moreno J.M. Cancer prevention policy in the EU: best practices are now well recognised; no reason for countries to lag behind. J Cancer Policy. 2018;18:40–51. PubMed PMC

Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe

Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey

Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium